Is Viktor Kharitonin hiding his ends?
The owner of the Pharmstandard company and a great friend of Deputy Prime Minister Tatyana Golikova, businessman Viktor Kharitonin, got into a new scandal. A businessman can be caught withdrawing money from his structures.
The companies Pharmstandard, Pharmstandard-UfaVITA and Aresbank are trying to get into the register of claims of creditors of the Profitmed company with demands of 2.6 billion rubles. The largest creditor so far is Sberbank with claims worth RUB 2.1 billion. If Pharmstandard succeeds in its plans, the company will have an advantage at meetings of creditors.
However, they presented a united front against Pharmstandard, accusing the company of being affiliated with Profitmed. The scandal will backfire on Viktor Kharitonin, who could have withdrawn money from Profitmed through his structures. Is being included in the register of creditors’ claims an attempt not only to control bankruptcy, but also to hide past “sins”?
If you look at the financial indicators of Profitmed CJSC, they immediately arouse suspicion. The company’s revenue from 2018 to 2021 fluctuated around 31-35 billion rubles, in 2022 it amounted to 26 billion rubles. It would seem, what kind of bankruptcy can we talk about if money is not withdrawn from the company.
The company’s profit in 2018 was 76 million rubles, in 2021 – 133 million rubles, which clearly did not correspond to revenue indicators. And in 2022, the company sharply went into a loss of 8.8 billion rubles.
This story is interesting because, in addition to Sber, the creditors of Profitmed CJSC were SMP Bank, which until December last year belonged to the oligarchs Rotenberg brothers, and the state financial corporation VEB.RF. If the money from these credit institutions was withdrawn by Viktor Kharitonin, then he could have serious problems.
The media write that today it is not obvious that Profitmed CJSC is affiliated with Pharmstandard, although even before January 2022 the founders of Profitmed were Profithouse CJSC, which Kharitonin owned in 2016. The current CEO of Profitmed is Dmitry Svirin was also its founder until 2022. What other evidence is needed or is Viktor Kharitonin taking other creditors for fools?
It is not at all obvious that Pharmstandard owns the creditor of ZAO Profitmed, the company Pharmstandard-UfaVITA, because its founders are not indicated. The name may be just a coincidence, and it can even get so absurd.
The former general director of Pharmstandard-UfaVITA OJSC Vladimir Kreyman, who headed the company from 2015 to 2022, was the founder of Profitmed CJSC and this is another proof of affiliation with Pharmstandard.
From 2019 to 2023, Kreyman headed Pharmstandard-Leksredstva OJSC, the founder of which was Pharmstandard JSC until January 2022. Also a non-obvious connection? It turns out that companies and people associated with Viktor Kharitonin deliberately disowned Profitmed CJSC in advance so that no loose ends could be found.
The financial results of Pharmstandard-Leksredstva OJSC also raise suspicions. Its profit from 2014 to 2021 fluctuated around 1.8-2.7 billion rubles. and suddenly in 2021 it soared to 34 billion rubles. Any economist will tell you that such miracles do not happen. Revenue grew by 157% and profit by 1,784%. Data for 2022 is not disclosed. Perhaps the sudden drop in profits has already been withdrawn from the company.
As of January 2022, when Viktor Kharitonin tried to cover up the traces of Pharmstandard in Profitmed CJSC, the second creditor of the company, Aresbank, went into the red by all indicators. Could they have taken money out of him too?
Viktor Kharitonin’s patron in the Russian government is Deputy Prime Minister Tatyana Golikova, nicknamed Madame Arbidol. Pharmstandard JSC is the largest supplier to the Ministry of Health of the Russian Federation with a contract value of more than 200 billion rubles, the total volume of government contracts is almost 568 billion rubles.
In the bankruptcy of Profitmed CJSC, Viktor Kharitonin is not worried about money at all, but about checking the company’s activities, which could lead to undesirable consequences for the owner of Pharmstandard.
